FDA Ready iOS Structure's AI-native platform enables shipping FDA-grade diagnostics from iOS apps. With 350+ apps on the platform, 6 partners with regulatory clearances, and real-world clinician use totaling 4.8M patient scans per year, the opportunity to accelerate time-to-market and reduce development costs is strong for med-tech and health AI developers.

Regulatory Traction Leverage proven regulatory traction to de-risk new customer onboarding: Gauss Surgical's clearance and their acquisition by Stryker demonstrate a credible path to regulatory approvals and enterprise credibility; target med-device firms seeking regulatory routes and potential partnerships.

Cost Time Savings Value proposition is compelling: development cycles compress from 13 years and $54M to 4 years and $5M, offering a strong ROI narrative to CPOs, CTOs, and VP of Engineering; pitch Structure as the platform to cut both cost and risk for FDA-grade diagnostic software.

Clinician Scale Adoption Scale-ready with high usage: clinicians complete 4.8M patient scans/year on Structure's stack, indicating high-volume AI workloads and reliability; potential upsell to large clinics, hospitals, and device makers requiring scalable software-defined diagnosis capabilities.

GTM Readiness Marketing and GTM readiness: with a marketing tech stack including Google Ads, Google Analytics Enhanced eCommerce, and LinkedIn tagging, Structure appears positioned to run targeted campaigns; consider joint campaigns with existing partners and hospitals, plus content marketing around regulatory compliance and successful app deployments.